Research Update Study News Today

Issuer: SphingoTec GmbH / Key word(s): Research Update/Study results New Formula Leverages Proenkephalin A 119-159 (penKid) for Improved GFR Estimation in Steady-State and Critically Ill Patients 05.10.2023 / 10:00 CET/CEST The issuer is solely responsible for the content of this announcement. P...

Issuer: SphingoTec GmbH / Key word(s): Research Update/Study results ADQI Group Recognizes PenKid as Relevant Functional Biomarker for Sepsis-Associated Acute Kidney Injury 04.04.2023 / 10:00 CET/CEST The issuer is solely responsible for the content of this announcement. The Acute Disease Qualit...

Issuer: SphingoTec GmbH / Key word(s): Research Update/Study results ADQI Group Recognizes PenKid as Relevant Functional Biomarker for Sepsis-Associated Acute Kidney Injury 04.04.2023

Kinarus Therapeutics Holding AG / Key word(s): Research Update/Study Kinarus Therapeutics Phase 2 KINFAST Covid-19 Clinical Trial Progress Update 21.02.2023 / 07:00 CET/CEST MEDIA RELEASE KINFAST is evaluating KIN001 for reduction in severity and duration of Covid-19 symptoms KINFAST is actively...

Kinarus Therapeutics Holding AG / Key word(s): Research Update/Study Kinarus Therapeutics Phase 2 KINFAST Covid-19 Clinical Trial Progress Update 21.02.2023 / 07:00 CET/CEST MEDIA

Kinarus Therapeutics Holding AG / Key word(s): Research Update/Study results Kinarus Therapeutics Reports Preclinical Data in Lung Fibrosis and Discloses Clinical Development Plan 17.01.2023

Kinarus Therapeutics Holding AG / Key word(s): Research Update/Study resultsKinarus Therapeutics Reports Preclinical Data in Lung Fibrosis and Discloses Clinical Development Plan 17.01.2023 / 07:00 CET/CESTMEDIA RELEASE KIN001 reduced fibrotic damage of the lung in a preclinical fibrosis model Potential as an effe...

EQS-News: Epigenomics AG / Key word(s): Research Update/Study results​​​​​​​Pareto Securities AS publishes buy recommendation for Epigenomics AG share 23.12.2022 / 07:00 CET/CESTThe issuer is solely responsible for the content of this announcement.Pareto Securities AS publishes buy recommendation for Epigenomics AG...

Spexis AG / Key word(s): Research Update/Study resultsSpexis announces promising pre-clinical data with balixafortide in combination with various therapies on the market for treating B-cell lymphomas 13.12.2022 / 07:30 CET/CESTAllschwil, Switzerland, December 13, 2022 Spexis announces promising pre-clinical dat...

Kinarus Therapeutics Holding AG / Key word(s): Research Update/Study Kinarus Therapeutics initiates KIN001 Phase II KINFAST clinical trial in...